Johnson & Johnson (opens in new tab) said on Monday that it had agreed to acquire Ollin Biosciences, a Texas-based biotechnology company, for $2.2 billion in cash upfront, with potential regulatory and commercial milestone payments of up to about $1.125 billion. The company said it expected the transaction to close before the end of 2026, subject to regulatory approvals and customary conditions. CNBC (opens in new tab), in a Reuters report, described the package as worth up to $3.33 billion and the milestone pot as about $1.13 billion.
The acquisition would add OLN324, an investigational bispecific antibody being developed for wet age-related macular degeneration and diabetic macular edema, J&J said. Fierce Biotech (opens in new tab) reported that Ollin has said the drug beat Roche's Vabysmo on measures of eye structure and vision in an early head-to-head study, a company claim, and that late-stage trials are planned. J&J said Blackstone Life Sciences will pay $750 million over several years to fully fund Phase 3 development, in return for certain regulatory and sales milestone payments and single-digit royalties.